Revvity Inc. stock (US76155R1086): Barclays lifts price target as Q1 beats estimates

Revvity Inc. stock trades near $100 after Barclays raised its price target to $105 and the company reported first?quarter 2026 results above expectations.

Revvity Inc. stock is trading near $100 on the New York Stock Exchange after Barclays lifted its 12?month price target to $105 from $95 and the company reported first?quarter 2026 results that beat Wall Street estimates, according to a research note dated May 7, 2026 and the company’s earnings release issued on May 7, 2026.MarketBeat as of 05/07/2026Revvity press release as of 05/07/2026

Shares of Revvity Inc. (ticker: RVTY) rose about 6.8% intraday on May 7, 2026, to around $92.38, according to the company’s investor relations page, which tracks real?time NYSE data.Revvity IR as of 05/07/2026 Barclays’ new target implies roughly 4.5% upside from the stock’s recent level, while the broader analyst consensus averages about $107.73, reflecting a mix of four buy, eight hold and one sell ratings.MarketBeat as of 05/07/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences and diagnostics
• Headquarters/country: Waltham, Massachusetts, United States
• Core markets: North America, Europe, Asia
• Key revenue drivers: Life science tools, diagnostics, and related services
• Home exchange/listing venue: New York Stock Exchange (NYSE: RVTY)
• Trading currency: U.S. dollar (USD)

Revvity Inc.: core business model

Revvity Inc. operates as a global provider of life science tools, diagnostics, and related services, serving pharmaceutical, biotechnology, academic, and clinical customers.Revvity press release as of 05/07/2026 The company’s portfolio spans instruments, reagents, software, and consumables used in drug discovery, development, and clinical diagnostics, positioning it at multiple stages of the biopharma value chain.

Revvity’s business model emphasizes recurring revenue streams from consumables, service contracts, and software subscriptions, which can help smooth demand versus one?time instrument sales.Revvity press release as of 05/07/2026 The company also focuses on integrating data?driven workflows and digital platforms to support customers’ research and diagnostic workflows, which can enhance customer stickiness and cross?selling opportunities.

Main revenue and product drivers for Revvity Inc.

In the first quarter of 2026, Revvity reported revenue of $711 million, up 7% year?over?year and above the prior?year figure of $665 million, according to its earnings release.Revvity press release as of 05/07/2026 On a pro forma basis, revenue was $687 million, reflecting 3% organic growth and 6% pro forma organic growth, indicating underlying demand in core life science and diagnostics segments.

Adjusted earnings per share from continuing operations came in at $1.06, beating the consensus estimate of $1.02, while GAAP EPS from continuing operations was $0.37 versus $0.35 in the same quarter of 2025.Revvity press release as of 05/07/2026MarketBeat as of 05/07/2026 GAAP operating income from continuing operations rose to $76 million from $72 million, with an operating margin of 10.7%, suggesting modest margin expansion despite ongoing investment in growth initiatives.

Revvity also updated its full?year 2026 guidance, projecting adjusted EPS from continuing operations of $5.20–$5.30, which aligns with or slightly exceeds prior expectations and supports the recent analyst optimism.Revvity press release as of 05/07/2026 The company additionally announced its intention to divest its China Immunodiagnostics business, which may streamline its portfolio and focus capital on higher?growth or higher?margin segments.

Conclusion

Revvity Inc. has delivered first?quarter 2026 results that beat consensus estimates on both revenue and adjusted EPS, while Barclays’ higher price target and the broader “hold”?rated analyst consensus reflect cautious optimism about the stock’s valuation and growth trajectory.Revvity press release as of 05/07/2026MarketBeat as of 05/07/2026 The company’s updated full?year guidance and planned divestiture of its China Immunodiagnostics business suggest a focus on core life science and diagnostics markets, which may appeal to investors seeking exposure to biopharma and clinical diagnostics trends.

For US investors, Revvity’s listing on the NYSE and its presence in North American life science and clinical markets provide direct access to a sector that benefits from ongoing drug discovery, precision medicine, and diagnostic innovation.Revvity press release as of 05/07/2026 However, the stock’s valuation, analyst rating mix, and execution risks around portfolio changes and global demand mean that investors should weigh both the growth potential and the inherent volatility of life science and diagnostics equities.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.